4,456 results match your criteria Expert opinion on pharmacotherapy[Journal]


Tasimelteon for treating non-24-h sleep-wake rhythm disorder.

Expert Opin Pharmacother 2019 Apr 16:1-9. Epub 2019 Apr 16.

a Sleep and Circadian Neurobiology Laboratory, Psychiatry and Behavior Sciences , Stanford University School of Medicine , Palo Alto , CA , USA.

Introduction: Non-24-h sleep-wake rhythm disorder (non-24) is observed in approximately half of totally blind individuals, a condition caused by their circadian pacemaker in the suprachiasmatic nucleus not being entrained to 24 h due to a lack of light perceptions. These subjects have a progressively delayed circadian cycle each day, non-24 periodically inducing nighttime insomnia and daytime sleepiness. Tasimelteon is a dual melatonin receptor agonist with high affinity for the melatonin 2 receptor, and it entrains endogenous melatonin rhythms and sleep-wake cycles in individuals with non-24. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1603293DOI Listing
April 2019
1 Read

Pharmacotherapy options and drug development in managing periprosthetic joint infections in the elderly.

Expert Opin Pharmacother 2019 Apr 14:1-13. Epub 2019 Apr 14.

a Department of Clinical Microbiology , IIS-Fundación Jiménez Díaz , Madrid , Spain.

Introduction: Prosthetic joint infections are an increasingly important problem among patients undergoing arthroplasty procedures, and are associated with significant morbidity, reduced quality of life, substantial healthcare costs, and even mortality. Arthroplasties are performed with increasing frequency in elderly patients, who present specific problems. Areas covered: Surgical therapy is clearly influenced by the clinical status of the patient, which in some case can contraindicate surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1602118DOI Listing

Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD).

Expert Opin Pharmacother 2019 Apr 14:1-11. Epub 2019 Apr 14.

a Pulmonary, Critical Care, Allergy and Sleep Medicine , Medical University of South Carolina , Charleston , SC , USA.

Introduction: Inhaled corticosteroid/long-acting β-2 agonists (ICS/LABA) combination inhalers have been a lifeline for a generation of chronic obstructive pulmonary disease (COPD) and asthma patients. Fluticasone furoate and Vilanterol (FF/VI) as a once-daily ICS/LABA combination have an extensive clinical trial and real-world data to support its use in COPD patients. Areas covered: The authors provide pharmacological profiles of fluticasone furoate, vilanterol and the FF/VI fixed dose combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1603292DOI Listing
April 2019
1 Read

Advancing pharmacotherapy for diabetic foot ulcers.

Expert Opin Pharmacother 2019 Apr 8:1-8. Epub 2019 Apr 8.

b Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine , Democritus University of Thrace , Alexandroupolis , Greece.

Introduction: Standard treatment for diabetic foot ulcers (DFUs) includes off-loading, debridement, moisture balance, management of infection and peripheral arterial disease (PAD) as well as adequate glycemic control. The outcomes so far are unsatisfactory. Areas covered: Herein, the authors provide an outline of newer pharmacological agents for the management of DFUs and give their expert perspectives on future treatment strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1598378DOI Listing
April 2019
1 Read

Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.

Expert Opin Pharmacother 2019 Apr 8:1-12. Epub 2019 Apr 8.

c Academic Orthopaedic Unit , Aristotle University Medical School, Papageorgiou General Hospital , Thessaloniki , Greece.

Introduction: Pharmacological options to address the imbalance between bone resorption and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique biologic pathways such as the Wnt/β-catenin pathway have been targeted in the quest for new emerging therapeutic strategies. Areas covered: This review provides an overview of existing pharmacotherapy for osteoporosis in women and explore state-of-the-art and emerging therapies to prevent bone loss, with an emphasis on the mechanism of action, indications and side effects. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1594772DOI Listing
April 2019
5 Reads

What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?

Expert Opin Pharmacother 2019 Apr 5:1-5. Epub 2019 Apr 5.

a Division of Hematology , Yale University Yale Cancer Center , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1599357DOI Listing
April 2019
1 Read

Pharmacotherapy for hypertension in pregnant patients: special considerations.

Expert Opin Pharmacother 2019 Apr 3:1-20. Epub 2019 Apr 3.

a Department of Pharmacology and Toxicology, School of Medicine , Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERCV , Madrid , Spain.

Introduction: Hypertensive disorders of pregnancy (HDP) represent a major cause of maternal, fetal and neonatal morbidity and mortality and identifies women at risk for cardiovascular and other chronic diseases later in life. When antihypertensive drugs are used during pregnancy, their benefit and harm to both mother and fetus should be evaluated. Areas covered: This review summarizes the pharmacological characteristics of the recommended antihypertensive drugs and their impact on mother and fetus when administered during pregnancy and/or post-partum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1594773DOI Listing
April 2019
8 Reads

What special considerations must be made for the pharmacotherapeutic management of heterozygous familial hypercholesterolemia?

Expert Opin Pharmacother 2019 Apr 1:1-6. Epub 2019 Apr 1.

a First Propedeutic Department of Internal Medicine, Medical School , Aristotle University of Thessaloniki, AHEPA Hospital , Thessaloniki , Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1598971DOI Listing
April 2019
2 Reads

Current and Promising Therapy for Primary Biliary Cholangitis.

Expert Opin Pharmacother 2019 Apr 1. Epub 2019 Apr 1.

a Mayo Clinic, Division of Gastroenterology and Hepatology , 200 1st St. SW, Rochester , MN.

Introduction: Primary biliary cholangitis is a chronic, cholestatic liver disease that may progress to cirrhosis with complications of end-stage liver disease. Approved treatment options include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) but novel therapies are being investigated. Areas covered: In this review, the authors describe the current pharmacotherapy for the treatment of primary biliary cholangitis (PBC) and for management of side effects such as pruritus and fatigue based on the currently available literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1601701DOI Listing
April 2019
9 Reads

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

Expert Opin Pharmacother 2019 Mar 29:1-7. Epub 2019 Mar 29.

b Diabetes Centre, Second Department of Internal Medicine , Democritus University of Thrace, University Hospital of Alexandroupolis , Alexandroupolis , Greece.

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1593372DOI Listing
March 2019
2 Reads
3.534 Impact Factor

Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

Expert Opin Pharmacother 2019 Mar 28:1-4. Epub 2019 Mar 28.

a Pharmacology Unit, Department of Medical and Surgical Sciences , University of Bologna , Bologna , Italy.

Introduction: Individuals with type 2 diabetes mellitus (T2DM) have increased cardiovascular risk with regulatory agencies requiring cardiovascular outcome trials (CVOTs) for the approval of new antidiabetic drugs. Areas covered: In this paper, the authors critically discuss the background, trial design, results and implications of a recent CVOT [NCT01730534; DECLARE-TIMI 58 study], which demonstrated that dapagliflozin was non-inferior to placebo in terms of major adverse cardiovascular events, and superior for the occurrence of hospitalization for heart failure (HF) and composite renal endpoints, thus confirming the cardiovascular benefit of sodium-glucose co-transporter-2 (SGLT2) inhibitors. No statistically-significant effects were found for amputations, fractures, and stroke (debated safety issues having emerged in previous CVOTs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1598970DOI Listing

When is pharmacotherapy required for children suffering from Generalized Anxiety Disorder?

Expert Opin Pharmacother 2019 Mar 28:1-4. Epub 2019 Mar 28.

a Department of Psychiatry , University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico , Milan , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1595583DOI Listing
March 2019
5 Reads

Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections.

Expert Opin Pharmacother 2019 Mar 25:1-5. Epub 2019 Mar 25.

a Department of Pharmacy , State University of New York Upstate University Hospital , Syracuse , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1594774DOI Listing

An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy.

Expert Opin Pharmacother 2019 Mar 25:1-7. Epub 2019 Mar 25.

b Department of Neurology and Rehabilitation Medicine , Skåne University Hospital , Lund , Sweden.

Introduction: About 70 million people worldwide are estimated to suffer from epilepsy. Despite a large variety of old and new antiepileptic drugs on the market, about 30% of people with epilepsy do not become seizure-free with medical treatment. This is a major individual and public health burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1595584DOI Listing
March 2019
2 Reads

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.

Expert Opin Pharmacother 2019 Mar 25:1-12. Epub 2019 Mar 25.

e Department of Cardiac Surgery, Shanghai East Hospital , Tongji University , Shanghai , China.

Introduction: Cardiovascular disease is a major cause of morbidity and mortality throughout the world and hypercholesterolemia is one of the key risk factors. Statins are the first line treatment to reduce atherogenic lipids and there is substantial and robust evidence with atorvastatin for reduction of cardiovascular events and mortality. Ezetimibe can be combined with any dose of atorvastatin for incremental lipid-lowering effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1594776DOI Listing
March 2019
4 Reads

Tadalafil for the treatment of benign prostatic hyperplasia.

Expert Opin Pharmacother 2019 Mar 22:1-9. Epub 2019 Mar 22.

a Department of Pharmacology, Faculty of Medical Sciences , University of Campinas , Campinas , Sao Paulo , Brazil.

Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement. Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1589452DOI Listing
March 2019
3 Reads

Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients.

Expert Opin Pharmacother 2019 Mar 21:1-12. Epub 2019 Mar 21.

b Department of Pediatrics , Childhood Asthma Atopy Center, Environmental Health Center, Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea.

Introduction: The social and medical costs of bronchiectasis in children are becoming considerable due to its increasing prevalence. Early identification and intensive treatment of bronchiectasis are needed to decrease the morbidity and mortality associated with bronchiectasis in children. Area covered: This review presents the current pharmacotherapeutic strategies for treating bronchiectasis in children with a focus on non-cystic fibrosis bronchiectasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1589453DOI Listing
March 2019
3 Reads

Pharmacotherapy for the treatment of vaginal atrophy.

Expert Opin Pharmacother 2019 May 21;20(7):821-835. Epub 2019 Mar 21.

d Department of Biothermodynamics and Drug Design , Vilnius University Institute of Biotechnology , Vilnius , Lithuania.

Introduction: Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574752DOI Listing
May 2019
3 Reads

Is there hope for spinal muscular atrophy synthetic pharmacotherapy?

Authors:
Markus Riessland

Expert Opin Pharmacother 2019 Mar 20:1-4. Epub 2019 Mar 20.

a Laboratory of Molecular and Cellular Neuroscience , The Rockefeller University , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1595585DOI Listing

Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain.

Expert Opin Pharmacother 2019 Mar 18:1-9. Epub 2019 Mar 18.

d Universidad de Buenos Aires, Facultad de Medicina, Departamento de Toxicología y Farmacología , Tercera Cátedra de Farmacología , Buenos Aires , Argentina.

Introduction: The obesity epidemic continues to grow. Bariatric surgery is part of the arsenal to treat the disease. Surgery results in an effective option for patients with severe obesity but also when obesity is associated with significant comorbidities. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1583746DOI Listing
March 2019
1 Read

Pharmacological management of sepsis in adults with a focus on the current gold standard treatments and promising adjunctive strategies: evidence from the last five years.

Expert Opin Pharmacother 2019 Mar 17:1-17. Epub 2019 Mar 17.

a 4th Department of Internal Medicine , National and Kapodistrian University of Athens, Medical School , Athens , Greece.

Introduction: The last five years, there have been considerable changes in our perception on the pathogenesis of sepsis. This review aims to summarize the current progress of the last five years in the management and research fields of sepsis in a holistic approach. To achieve this, accumulated evidence over the last five years coming from randomized clinical trials (RCTs) and observational studies in adults for the management of sepsis is provided. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1589451DOI Listing
March 2019
4 Reads

Current state-of-the-art pharmacotherapy for the management of hepatitis B infection.

Expert Opin Pharmacother 2019 May 11;20(7):873-885. Epub 2019 Mar 11.

a Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Brody School of Medicine , East Carolina University , Greenville , NC , USA.

Introduction: Hepatitis B virus (HBV) infection remains a global challenge with several hundred million infected individuals. Disease activity can be controlled, and adverse outcomes prevented when treatment can be provided. Frequently life-long therapy is required instead of defined treatment periods such as with the case of Hepatitis C Virus (HCV) infection. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1583744DOI Listing
May 2019
3 Reads

Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.

Expert Opin Pharmacother 2019 May 11;20(7):805-811. Epub 2019 Mar 11.

a Department of Medicine, Surgery and Neurosciences , University of Siena , Siena , Italy.

Introduction: Osteoporosis is a skeletal disorder characterized by loss of bone mass and strength affecting up to 30-50% of postmenopausal women worldwide. Current therapeutic options include antiresorptives such as aminobisphosphonates or denosumab and osteoanabolic compounds such as teriparatide. Areas covered: In this review, the authors summarize the clinical development, safety and efficacy profile of abaloparatide, a new osteoanabolic agent recently marketed in the US for the treatment of postmenopausal osteoporosis in women who are at high risk for fracture or who fail antiresorptive therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1583208DOI Listing

Current pharmacotherapy for testicular germ cell cancer.

Expert Opin Pharmacother 2019 May 8;20(7):837-850. Epub 2019 Mar 8.

a Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology , University Medical Center Eppendorf , Hamburg , Germany.

Introduction: With the implementation of platinum-based chemotherapy, germ cell tumors (GCTs) became a model for a curable solid tumor, with survival rates of 95% in all patients with >80% survival in metastatic stages. Areas covered: Herein, the authors review the current standards of adjuvant chemotherapy for stage I GCTs as well as first-line and salvage treatments for metastatic disease. Novel approaches for refractory disease are also reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1583745DOI Listing
May 2019
2 Reads

New and emerging drugs for the treatment of acne vulgaris in adolescents.

Expert Opin Pharmacother 2019 Mar 8:1-16. Epub 2019 Mar 8.

a Department of Dermatology , ABC Hospital , Mexico City , Mexico.

Introduction: Acne vulgaris is the most common skin disease worldwide, yet current treatment options, although effective, are associated with unwanted side effects, chronicity, relapses and recurrences. The adequate control of the four pathogenic mechanisms involved in the appearance of acne lesions is key to treatment success. This paper aims to discuss the novel treatment modalities that have surfaced in consequence of new knowledge obtained in acne pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1584182DOI Listing
March 2019
1 Read

An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.

Expert Opin Pharmacother 2019 May 5;20(7):781-790. Epub 2019 Mar 5.

a Diabetes Medical Center , Tel Aviv , Israel.

Introduction: Accumulating data from recent studies has altered the gold standard of care for diabetes treatment. In patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or those at high risk for CVD, subsequently to lifestyle changes and metformin therapy, the administration of an SGLT-2 inhibitor with established benefits for cardiovascular outcome (CVOT) should be considered. Areas covered: Tofogliflozin is the most selective SGLT-2 inhibitor and has been approved for the treatment of T2D in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1583210DOI Listing
May 2019
3 Reads

Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients.

Expert Opin Pharmacother 2019 Mar 4:1-11. Epub 2019 Mar 4.

a Medical Division , Novartis Pharma K.K ., Tokyo , Japan.

Background: Vildagliptin is indicated for type 2 diabetes mellitus (T2DM); however, the onset and exacerbation of diabetic complications in Japanese T2DM patients treated with vildagliptin is unknown.

Research Design And Methods: This 2-year post-marketing surveillance (PMS) assessed the real-world safety and efficacy of vildagliptin therapy in 19,218 Japanese T2DM patients. The relationship between the incidence of macro- and microvascular complications with patient characteristics and changes in glycemic control (HbA1c) were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1585802DOI Listing
March 2019
7 Reads

ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.

Expert Opin Pharmacother 2019 May 27;20(7):791-803. Epub 2019 Feb 27.

h Dyslipidemia Center , A.S.S.T. Grande Ospedale Metropolitano Niguarda , Milan , Italy.

Introduction: Tolerability problems in treating hypercholesterolemic patients undergoing statin treatment are of growing concern to physicians and patients, thus underlining the need for an agent with a similar mechanism but minimal side effects. A drug with a somewhat similar mechanism to statins but free of muscular side effects is ETC-1002 (bempedoic acid). It inhibits cholesterol biosynthesis at a step preceding HMG-CoA reductase, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1583209DOI Listing
May 2019
1 Read

State of the art opioid-sparing strategies for post-operative pain in adult surgical patients.

Expert Opin Pharmacother 2019 Feb 27:1-13. Epub 2019 Feb 27.

a Department of Anesthesiology, Division of Regional Anesthesia and Acute Pain , University of California , San Diego, La Jolla , CA , USA.

Introduction: There are various important implications associated with poorly controlled postoperative pain in the adult surgical patient - this includes cardiopulmonary complications, opioid-related side effects, unplanned hospital admissions, prolonged hospital stay, and the subsequent development of chronic pain or opioid addiction. With the ongoing national opioid crisis, it is imperative that perioperative providers implement pathways for surgical patients that reduce opioid requirements and pain-related complications. Areas covered: In this review, the authors discuss the components of a multimodal opioid-sparing analgesia pathway as it pertains to the perioperative environment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1583743DOI Listing
February 2019

What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?

Expert Opin Pharmacother 2019 May 26;20(7):777-779. Epub 2019 Feb 26.

a Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, Obstetrics and Gynecology Unit, IRCCS S. Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences , University of Pavia , Pavia , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1582644DOI Listing
May 2019
1 Read

The pharmacological management of patients with comorbid psoriasis and obesity.

Expert Opin Pharmacother 2019 May 22;20(7):863-872. Epub 2019 Feb 22.

b Section of Dermatology and Venereology, Department of Medicine , University of Verona , Verona , Italy.

Introduction: Psoriasis is a chronic inflammatory skin disease that is increasingly being recognized as a complex disorder affecting multiple systems. Systemic inflammation is considered the pathogenic link between psoriasis and its comorbid conditions that include arthritis, metabolic disorders, depression, and cardiovascular diseases. The presence of comorbid conditions modifies both its clinical management and the therapeutic approach in psoriatic patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1583207DOI Listing

Drug treatment strategies for insomnia in patients with post-traumatic stress disorder.

Expert Opin Pharmacother 2019 Apr 22;20(6):691-699. Epub 2019 Feb 22.

b Department of Medicine , VA Western New York Healthcare System , Buffalo , NY , USA.

Introduction: Insomnia is among the most reported sleep disturbances in patients with post-traumatic stress disorder (PTSD). The pervasiveness of this disorder among trauma-inflicted civilians and military personnel has been associated with reduced quality of life, impaired psychosocial functioning including cognitive impairments, negative mood swings, cardiovascular complications, and increased utilization of medical services. Areas covered: This review describes the current state of science with respect to the impact of the most dispensed pharmacological interventions for posttraumatic insomnia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574745DOI Listing
April 2019
4 Reads

Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all?

Expert Opin Pharmacother 2019 May 22;20(7):773-775. Epub 2019 Feb 22.

a Department of Internal Medicine , Virginia Commonwealth University , Richmond , VA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1582643DOI Listing

Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery.

Expert Opin Pharmacother 2019 Apr 20;20(6):751-772. Epub 2019 Feb 20.

a Dipartimento di Scienze della Salute (DISSAL) , University of Genoa , Genoa , Italy.

Introduction: Patients undergoing open-heart surgery may suffer from postoperative complications, including severe infections. Antimicrobials to treat infectious complications in this population should be selected thoughtfully, taking into account three different and fundamental issues: (i) the site of infection; (ii) the suspected or proven causative agent and its susceptibility pattern; and (iii) the risk of suboptimal pharmacokinetic characteristics and potential toxicity of the chosen drug/s. Areas covered: The present narrative review summarizes the current and future antimicrobial options for the treatment of infections developing after open-heart surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574753DOI Listing
April 2019
2 Reads

The pharmacologic management of multiple myeloma in older adults.

Expert Opin Pharmacother 2019 May 20;20(7):887-902. Epub 2019 Feb 20.

d Department of Medicine, Division of Hematology and Oncology , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Multiple myeloma is a disease predominately affecting older adults. Pivotal to treating older adults is understanding their physiologic differences compared to younger subjects and how the complexity of therapies has an impact upon this patient population. Areas covered: Herein, the authors address the efficacy of chemotherapy regimens, decision-making for older adults, chemotherapy-associated toxicity and the approach to management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1577822DOI Listing

Agomelatine for depression: expanding the horizons?

Expert Opin Pharmacother 2019 Apr 13;20(6):647-656. Epub 2019 Feb 13.

a Department of Psychiatry , University of Melbourne, Austin Hospital , Heidelberg , Australia.

Introduction: Agomelatine is an antidepressant with unique pharmacological actions; it is both a melatonin agonist and selective serotonin antagonist. Both actions combined are necessary for antidepressant efficacy. Effects on melatonin receptors enable resynchronisation of disrupted circadian rhythms with beneficial effects on sleep patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574747DOI Listing
April 2019
110 Reads
3.534 Impact Factor

Zoledronic acid for the treatment of prostate cancer.

Expert Opin Pharmacother 2019 Apr 7;20(6):657-666. Epub 2019 Feb 7.

b Genitourinary Oncology , Inova Schar Cancer Institute , Fairfax , VA , USA.

Introduction: Prostate cancer remains the most common solid tumor afflicting men in the developed world. Metastatic prostate cancer is a source of great morbidity and mortality especially due to osseous involvement that gives rise to significant symptoms of pain or pathologic fractures or cord compression. Bisphosphonates had been widely used in the treatment of metastatic prostate bone metastases given their demonstrated benefit with a delay of skeletal-related events (SREs) but without prostate-specific antigen (PSA) response or overall survival benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574754DOI Listing
April 2019
2 Reads

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.

Expert Opin Pharmacother 2019 Apr 7;20(5):501-510. Epub 2019 Feb 7.

a Clinical Metabolic Physiology , Steno Diabetes Center Copenhagen , Gentofte , Denmark.

Introduction: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571040DOI Listing
April 2019
1 Read

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.

Expert Opin Pharmacother 2019 Apr 7;20(6):635-645. Epub 2019 Feb 7.

c Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center , Université de Toulouse UPS, CHU de Toulouse, INSERM , Toulouse , France.

Introduction: L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson's disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA), familial amyloid polyneuropathy, and hemodialysis. Recently, the FDA has approved its use in symptomatic neurogenic orthostatic hypotension (NOH). Areas covered: The authors review the effects of droxidopa in NOH with a focus on the neurodegenerative diseases PD, MSA, and pure autonomic failure (PAF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574746DOI Listing
April 2019
5 Reads

Pharmacotherapeutic options for patients with refractory breast cancer.

Expert Opin Pharmacother 2019 May 7;20(7):851-861. Epub 2019 Feb 7.

a Medical Oncology & Breast Unit , "Antonio Perrino" Hospital , Brindisi , Italy.

Introduction: The development of resistance to therapy is a concern in all three subtypes of breast cancer (BC). Yet, outcomes of patients with BC have improved in the past few years thanks to a molecularly targeted approach and a greater understanding of the many mechanisms through which cancer cells adapt to evade drug therapies. Indeed, there have been a number of different and active treatment strategies for hormone receptor positive (HR+ and Her2 positive BC although triple-negative breast cancer treatment remains problematical because of the early onset of resistance to treatments and the limited availability of targeted treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574751DOI Listing
May 2019
4 Reads

Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?

Authors:
Jay Khastgir

Expert Opin Pharmacother 2019 May 6;20(7):813-820. Epub 2019 Feb 6.

a Swansea University Medical School , Abertawe Bro Morganwwg University Health Board , Swansea , Wales , UK.

Introduction: The use of antimuscarinic drugs is common in the management of the overactive bladder (OAB). Concerns have been raised over their use in the elderly population in whom the use of these drugs is highly prevalent, consequent to the reported link between these drugs and cognitive impairment and dementia. Areas covered: Recent publications have heightened concerns regarding antimuscarinic drug use in the elderly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574749DOI Listing
May 2019
2 Reads

Choosing the right pharmacotherapeutic strategy for HIV maintenance in patients with alcohol addiction.

Expert Opin Pharmacother 2019 Apr 6;20(6):631-633. Epub 2019 Feb 6.

a College of Pharmacy, Department of Pharmaceutical Sciences , University of Tennessee Health Science Center , Memphis , TN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574748DOI Listing
April 2019
5 Reads
3.534 Impact Factor

Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.

Expert Opin Pharmacother 2019 Apr 6;20(6):713-723. Epub 2019 Feb 6.

a Academic Unit of Obstetrics and Gynecology , IRCCS Ospedale Policlinico San Martino , Genoa , Italy.

Introduction: Uterine leiomyosarcomas (ULMS) account for 1% of all uterine malignancies and for 30% of all uterine sarcomas. The preoperative diagnosis of ULMS is challenging for the physicians, as the symptoms of these tumors are often vague and nonspecific. Moreover, as ULMS have an aggressive biologic behavior, affected women frequently have very poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571042DOI Listing
April 2019
15 Reads
3.534 Impact Factor

An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.

Expert Opin Pharmacother 2019 Apr 5;20(5):609-620. Epub 2019 Feb 5.

a Department of Medicine , McMaster University , Hamilton , ON , Canada.

Introduction: Asthma is a common chronic airway inflammatory disease characterized by diverse inflammatory events leading to airway hyperresponsiveness and reversible airflow obstruction. Corticosteroids have been the mainstay for asthma treatment due to their broad anti-inflammatory actions; however, other medications such as phosphodiesterase 4 inhibitors also demonstrate anti-inflammatory activity in the airways. Areas covered: This review describes tissue expression of phosphodiesterase 4 in the airways, the different phosphodiesterase 4 isoenzymes identified, and the anti-inflammatory activities of phosphodiesterase 4 inhibition in asthma and related findings in chronic obstructive pulmonary disease (COPD). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1570132DOI Listing
April 2019
12 Reads

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Expert Opin Pharmacother 2019 Apr 1;20(6):737-750. Epub 2019 Feb 1.

b Division of Respiratory Medicine , University Hospital "Tor Vergata" , Rome , Italy.

Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-dimensional approach, taking into account both symptoms of the patient and the number of acute exacerbations of COPD (AECOPDs). There are three main pharmaceutical classes currently available including long-acting muscarinic antagonists (LAMA), long-acting β-agonists (LABA) and inhaled corticosteroids (ICS). COPD is a major risk factor for most cardiovascular diseases, and cardiac comorbidities are very common in COPD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1570133DOI Listing
April 2019
1 Read

Current and emerging pharmacotherapy for emergency management of preeclampsia.

Expert Opin Pharmacother 2019 Apr 1;20(6):701-712. Epub 2019 Feb 1.

a Ritchie Centre, Department of Obstetrics and GynaecologySchool of Clinical Sciences , Monash University , Clayton , Australia.

Introduction: Preeclampsia is a disease specific to pregnancy characterised by new onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For fifty years, antihypertensives have been the mainstay of treating preeclampsia, reducing maternal morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1570134DOI Listing
April 2019
4 Reads

Current pharmacotherapy options for conduct disorders in adolescents and children.

Expert Opin Pharmacother 2019 Apr 31;20(5):571-583. Epub 2019 Jan 31.

h Townsville Clinical School, College of Medicine and Dentistry , James Cook University , Townsville , Australia.

Introduction: Conduct disorder (CD) is a common mental health disorder of childhood and adolescence. CD's complexity, with its heterogenous clinical manifestations and overlapping comorbidities makes the application of evidence-based management approaches challenging. This article aims to combine a systematic review of the available literature, with a consensus opinion from both child and adolescent psychiatrists and developmental pediatricians on the clinical and pharmacological management of children and adolescents with conduct disorder (CD). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1561862DOI Listing
April 2019
30 Reads

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.

Expert Opin Pharmacother 2019 Mar 30;20(4):385-397. Epub 2019 Jan 30.

a Lady Davis Institute for Medical Research, Jewish General Hospital , McGill University AIDS Centre , Montréal , Québec , Canada.

Introduction: Current antiretroviral therapy is more effective and simpler than in previous times due to the development of new drugs with improved pharmacokinetic and pharmacodynamic profiles and the advent of single pill regimens with low toxicity that facilitate long-term adherence. The recent approval of the novel potent integrase strand-transfer inhibitor bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) in a fixed daily dose pill, B/F/TAF, adds to the list of single-tablet regimens available to treat HIV infection. Areas covered: This review provides an overview of the pharmacological and clinical information obtained from MEDLINE/PubMed publications and the latest international conferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1560423DOI Listing

Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice.

Expert Opin Pharmacother 2019 Apr 29;20(6):679-690. Epub 2019 Jan 29.

a Department of Molecular and Developmental Medicine , University of Siena , Siena , Italy.

Introduction: Binge eating disorder (BED) is the most common eating disorder and was newly recognized in 2013 in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). BED is frequently associated with obesity and the metabolic syndrome, as well as with other psychiatric diseases, such as mood (49%), anxiety (41%), and substance use (22%) disorders. BED is highly prevalent and carries a high burden of mental and physical illness and disability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571041DOI Listing
April 2019
1 Read

Pharmacotherapy for onychomycosis: new and emerging treatments.

Authors:
Shari R Lipner

Expert Opin Pharmacother 2019 Apr 28;20(6):725-735. Epub 2019 Jan 28.

a Department of Dermatology , Weill Cornell Medicine , New York , NY , USA.

Introduction: Onychomycosis is the most common nail disorder seen in clinical practice. It is not merely an aesthetic disorder and may cause significant disability and affect the quality of life. There are no strict guidelines for onychomycosis therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571039DOI Listing
April 2019
5 Reads